HRT vs. BHRT: What Is the Difference and Which One Is Right for You?
When hormone replacement therapy comes up, many patients assume it refers to a single category of treatment. In reality, there are meaningful differences between conventional hormone replacement therapy (HRT) and bioidentical hormone replacement therapy (BHRT) — differences that go beyond marketing language and into the underlying biology. Understanding those distinctions can help you have a more informed conversation with your provider and make the decision that best fits your health history and goals.
Molecular Structure: The Core Difference
The most fundamental distinction is molecular. Bioidentical hormones have a chemical structure that is identical to the hormones produced naturally by the human body. Bioidentical estradiol is the same molecule as the estradiol your ovaries produce. Bioidentical progesterone is the same molecule your corpus luteum secretes. Bioidentical testosterone is the same molecule your adrenal glands and ovaries (in women) or testes (in men) manufacture.
Conventional synthetic HRT uses hormones that are deliberately modified. Conjugated equine estrogens (Premarin), derived from pregnant mare urine, contain a mixture of estrogen compounds that exist naturally in horses but not in the human female body. Medroxyprogesterone acetate (Provera) is a synthetic progestin engineered to mimic some of progesterone's actions but with a structurally different molecule that also interacts with androgen and glucocorticoid receptors in ways natural progesterone does not. These molecular differences produce different interactions with hormone receptors throughout the body — in the brain, breast tissue, cardiovascular system, and bone.
FDA Approval Status
Both conventional HRT and certain bioidentical hormone products are FDA-approved. FDA-approved bioidentical options include estradiol products (Estrace, Vivelle-Dot, Climara, Divigel), micronized progesterone (Prometrium), and testosterone (though testosterone products are currently approved only for men). Compounded bioidentical hormones — formulated by licensed compounding pharmacies to meet individual dose needs — are not individually FDA-approved products, but the active pharmaceutical ingredients used are FDA-approved, and the pharmacies are regulated by state boards and federal law.
The WHI Study in Context
The Women's Health Initiative study, whose alarming 2002 results led to a dramatic drop in HRT use, used conjugated equine estrogens and medroxyprogesterone acetate — synthetic hormones, not bioidentical ones. The elevated breast cancer risk identified in that study has been specifically linked to the synthetic progestin component. The estrogen-only arm of the same study, involving women who had undergone hysterectomy, actually showed a reduced risk of breast cancer after 18 years of follow-up. Subsequent re-analyses have also shown that the cardiovascular risks seen in the WHI were largely confined to older women who began therapy more than 10 years after menopause — the so-called "timing hypothesis" or "window of opportunity" principle.
These nuances matter enormously when evaluating risk. Applying WHI findings about synthetic hormones to bioidentical hormones is not scientifically justified.
Bioidentical Advantages
Bioidentical progesterone, compared to synthetic progestins, has a significantly better side-effect profile. It does not carry the same increased clotting and cardiovascular risks, it has a mild sedative effect that many women find beneficial for sleep, and it does not appear to carry the same elevation in breast cancer risk. Studies comparing bioidentical progesterone to medroxyprogesterone acetate in the KEEPS and E3N cohort trials found more favorable outcomes on cardiovascular markers and breast tissue density with bioidentical progesterone.
Delivery method flexibility is another advantage. BHRT can be administered via pellets, creams, gels, sublingual drops, or oral capsules, whereas conventional HRT options are more limited. This allows the provider to choose the route that best suits the patient's metabolism, lifestyle, and medical history — including avoiding first-pass hepatic metabolism when appropriate.
Who Should Choose Each?
Conventional synthetic HRT may be appropriate when cost is a primary constraint, when a patient is already stable and symptom-free on an existing regimen, or when specific FDA-approved indications (such as osteoporosis prevention with proven agents) are the primary goal. Bioidentical HRT is generally preferred when precise dose customization is needed, when a patient has had side effects with synthetic hormones, when there is a desire to avoid the theoretical risks associated with synthetic progestins, or when the provider wants to replicate physiologic hormone patterns as closely as possible.
The right choice ultimately depends on your personal health history, risk factors, symptoms, and goals — which is why this decision should be made with a specialist who understands the full picture.
Dr. Kenton Bruice MD specializes exclusively in bioidentical hormone replacement therapy at his clinics in Denver, Aspen, and St. Louis. If you would like an expert evaluation of whether BHRT is the right approach for you, contact his office to schedule a comprehensive consultation.